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http://www.biomedcentral.com/1471-244X/13/193RESEARCH ARTICLE Open AccessComparably high retention and low relapse rates
in different subpopulations of bipolar patients in
a German non-interventional study
Susanne Kraemer1*†, Anette Minarzyk1†, Steffen Eppendorfer1†, Carsten Henneges1†, Hans-Peter Hundemer1†,
Stefan Wilhelm1† and Heinz Grunze2†Abstract
Background: Although a range of pharmacotherapeutical options are available for the treatment of bipolar
disorder, patient non-adherence to prescribed treatment regimens and early treatment discontinuation remain
among the primary obstacles to effective treatment. Therefore, this observational study assessed time on mood
stabilizing medication and retention rates in patients with bipolar disorder (BD).
Methods: In an 18-month, prospective, multicenter, non-interventional study conducted in Germany 761 outpatients
(≥18 years) with BD and on maintenance therapy were documented. For analysis, patients were stratified by baseline
medication: monotherapy olanzapine (OM, N = 186), lithium (LM, N = 152), anticonvulsants (N = 216), other mood
stabilizing medication (OMS, N = 44); combination therapy olanzapine/lithium (N = 47), olanzapine/anticonvulsant
(N = 68), other combinations (OC, N = 48). Continuation on medication was assessed as retention rates with 95%
confidence intervals. Time to discontinuation and relapse-free time were calculated by Kaplan-Meier analysis. A relapse
was defined as increase to CGI-BP >3, worsening of CGI-BP by ≥2 points, hospitalization or death related to BD. A Cox
regression was calculated for the discontinuation of mood stabilizing therapy (reference: OM). Logistic regression models
with stepwise forward selection were used to explore possible predictors of maintenance of treatment and relapse.
Results: After 540 days (18 months), the overall retention rate of baseline medication was 87.7%, without notable
differences between the cohorts. The overall mean time on mood stabilizing treatment was 444.7 days, with a range of
377.5 (OMS) to 481 (LM) by cohort. 74.0% of all patients were without relapse, with rates between the cohorts ranging
from 58.4% (OC) to 80.2% (LM).
Conclusions: Retention rates exceeded controlled trial results in all treatment cohorts, in addition to other explanations
possibly reflecting that the physicians were expertly adapting treatment regimens to the individual patient’s disease
characteristics and special needs.
Keywords: Bipolar disorder, Retention, Relapse, Out-patient setting, Medication regimenBackground
Bipolar disorder (BD) is a common illness characterized
by recurrent episodes of mania and depression, as well
as mixed episodes. In the year 2000, BD ranked high in
the burden of disease in disability adjusted life-years
(DALYs) according to WHO [1].* Correspondence: kraemer_susanne@lilly.com
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reproduction in any medium, provided the orIn the same year in Germany a total of 343,500 days in
hospital were necessary due to a primary diagnosis of bi-
polar disorder (ICD F31). In addition, in indirect costs
370,000 days of sick leave were documented [2]. Suicide
rates are alarmingly high in bipolar patients (up to 20%)
[3]. As the disease is not only of high socio-economic sig-
nificance but as well of high pertinence for the patients’
personal well-being, reliable and agreeable pharmacological
relapse prevention is needed [3]. Though pharmacotherapy
is available for the treatment of bipolar disorder, pa-
tient non-adherence to prescribed treatment regimensl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the primary obstacles to effective treatment [6]. Keck et
al [7] found 52.8% of initially hospitalized patients with
mania or mixed episodes were partially or totally non-
adherent to their medication at the end of a 1 year
longitudinal open study (N = 106). Observations from a
Danish register-based cohort study indicate significantly
lower hospitalization rates for bipolar patients on lithium
compared with the anticonvulsants valproate [8] or
lamotrigine [9] started on relapse prevention treatment
when acutely ill, while no difference was seen in patients
who started it while in remission. The studies of Keck et
al [7,10] were mainly focused on lithium alone. But the
use of antipsychotics for maintenance therapy of bipolar
disorder has been investigated as well [11-13].
Guidelines for the treatment of bipolar disorder
[6,14-16] emphasize the importance of maintenance ther-
apy with mood stabilizers. However, randomized con-
trolled trials only partially reflect the complexity of
treating patients with bipolar disorder in everyday clinical
practice, which is highlighted by high relapse and discon-
tinuation rates in this type of study [17].
To address this gap, we designed a prospective non-
interventional study with the primary objective to assess
time on mood stabilizing therapy and retention rates in
naturalistic settings.
Methods
Study objectives
The primary objective of our study conducted by Lilly
Germany was to assess the time on different mood stabiliz-
ing medications and retention rates in standard clinical
care. Further objectives addressed relapse rates, patient ad-
herence, and tolerability.
Sample size estimation
At the time of protocol development, German market
research reported rates of approximately 30% olanzapine
use as a mood-stabilizing therapy. Based on this, it was
planned to distribute 600 data collection forms to about
100 study sites. With an estimated return rate of 80%,
500 patients were planned to be documented, with ap-
proximately 150 patients treated with olanzapine and
350 patients with other medications. Tohen et al [17]
found retention rates of 47% for patients treated with
olanzapine and 33% for patients treated with lithium in
an 18-month clinical trial for relapse prevention in bipo-
lar disorder. Assuming a similar range of retention rates,
two-sided 95% confidence intervals of the cohorts in
the present study would have a range of about 8%
(olanzapine, N = 150) and about 4.9% (other treatments
including lithium, N = 350). Thus, the targeted sample
size of 500 patients seemed to be adequate for achieving
the main objective of assessing time on mood stabilizingmedication and retention rates in patients with bipolar
disorder over a period of 18 months.
Study design and participants
This 18-month, prospective, multicenter, non-interventional
study was conducted by hospital and office based psy-
chiatrists throughout Germany between November 2004
and July 2007. Outpatients aged ≥18 years were enrolled
if they 1) had experienced a bipolar episode within the
last 6 months prior to the start of the study, which was
successfully treated to remission, and 2) the patient re-
quired pharmacological maintenance treatment for mood
stabilization. Remission was defined as a Clinical Global
Impression-Bipolar (CGI-BP) score of ≤3 [18,19]. In line
with the observational design of the study, treatment de-
cisions were entirely at the physicians’ and the patients’
discretion. No other in- or exclusion criteria were de-
fined; in particular having other psychiatric diagnoses be-
sides bipolar disease was not regarded an exclusion
criterion as in clinical practice patients often are treated
according to their most prominent symptoms, but suffer
from additional diseases, as well. No specific medication
strategy was asked for by the study protocol. But it
should be noted that at the time of data collection
olanzapine was already established in the treatment
of bipolar disorder, while other antipsychotic medications
like quetiapine or aripiprazole had not yet been approved
for the treatment of bipolar disorder. Written informed
consent for the release of clinical data was obtained from
all patients enrolled. The study was approved by the re-
sponsible ethical review board (of Medical Faculty of
Ludwig-Maximilians Universität Munich) and conducted
in accordance with the ethical standards of the Declar-
ation of Helsinki.
After the initial documentation at baseline (Visit 1),
data collection during the further course of routine
clinical practice was scheduled in 7 visits at approxi-
mately 3, 6, 9, 12, 15, and 18 months or at early
discontinuation.
At baseline, patient demographics and characteristics
were collected, including the history of bipolar disease,
working status, social environment, alcohol/substance
consumption or substance abuse, and concomitant
psychiatric disorders following ICD criteria [20]. Any
pharmacological treatment for bipolar relapse preven-
tion, i.e. treatment with mood stabilizers and other con-
comitant psychotropic medications was documented at
every visit, including dosage, any change in treatment as
well as time point and reasons for switch or discon-
tinuation. Further parameters assessed over the course
of the study were concomitant non-psychiatric medi-
cation, hospitalization due to psychiatric disorder, tol-
erability, suicidality, and solicited and unsolicited adverse
events (AEs).
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The Clinical Global Impression scale – Bipolar (CGI-BP)
is a general measure of illness severity adapted for bipo-
lar disease with scores ranging from 1 (normal, not at
all ill) to 7 (among the most extremely ill patients).
Three different versions address manic, depressive and
overall symptom severity (CGI-BP-manic, -depressive
and -total, respectively). For evaluation, the CGI-BP re-
sults were dichotomized into patients with scores of ≤3
(patients in remission) and patients with scores >3
(no remission or relapse).
A CGI-BP increase to >3 after baseline, worsening of a
minimum of 2 CGI-points, hospitalization due to psychi-
atric disorder, or death related to bipolar disorder were
counted as relapse.
The Drug Attitude Inventory (DAI) was used to assess
the patients’ attitude towards their medication (DAI-10,
short version [21]). It is a 10-item self rating scale with a
total score ranging between +10 and −10 (higher values
indicating more positive attitude towards medication).
Additionally, drug adherence was estimated by the
physician at every visit, judging how reliable the patients
were in taking their medication: approx. 100%, 75%,
50%, 25%, 0% - or reliability not accessible.
Safety and tolerability
Drug safety was evaluated for all patients who took at
least one dose of bipolar maintenance medication. Gen-
eral tolerability was assessed with the CGI-Tolerability
scale (CGI-T) [18] at every visit. The score ranges from
1 (no side effects) to 4 (side effects outweigh thera-
peutic effect). Results were dichotomized into ≤3 or >3,
“no side effects” plus “side effects which do not affect the
patient significantly” and “side effects which affect the pa-
tient significantly” plus “side effects that outweigh the
therapeutic effect”.
All treatment-emergent adverse events (TEAEs) reported
during the study were collected and coded according
to the Medical Dictionary for Regulatory Activities
(MedDRA). Serious adverse events (SAEs), discontinua-
tions due to AEs, and related AEs were analyzed descrip-
tively as appropriate. Additionally, a check list, assessing
the presence and clinical relevance of solicited possible
adverse reactions to mood stabilizers (according to these
substances’ established safety profiles) was completed at
every visit.
Statistics
Statistical evaluation was largely descriptive for demo-
graphic and baseline analyses, including the time on mood
stabilizing treatments. For quantitative variables means,
medians, standard deviations, minimum, maximum, and
quartiles, as well as the respective available sample size and
the number of missing values were calculated. Categoricalvariables were described by absolute and relative frequen-
cies (adjusted relative frequencies where appropriate).
SAS (SAS Institute Inc., version 9.1.3) was used for statis-
tical analyses.
The primary objective, treatment continuation, of this
study, was measured as retention rate with two-sided
95% CIs of patients in the respective treatment cohort.
Mean values for time on initial treatment were calcu-
lated for the different cohorts. Kaplan-Meier plots were
created to describe the time to discontinuation of the
baseline medication. To estimate the influence of type of
medication on time on initial treatment, a Cox-regression
model was calculated with time to discontinuation as
dependent variable, considering the main cohorts and the
following confounders: age (in years), sex (reference =
female), employment (yes/no, reference = no), stable
social environment (yes/no, reference = no), severity of
last bipolar episode (CGI-BP ≤3 vs. >3, reference = ≤3),
rapid cycling (yes/no, reference = no), history of psychi-
atric hospitalizations (number), psychiatric comorbidities
(yes/no for each code, reference = no), alcohol/drug
abuse (categorical [unknown and missing pooled],
reference = no), BMI (in kg/m2), concomitant psychiatric
medication at baseline (reference = no additional medica-
tion), number of previous bipolar episodes since onset of
disease (number), number of previous manic, depressive
and mixed episodes in the last 12 months (categories 0,
1, >1). Observations with missing values were excluded
from the model.
Furthermore, in a post hoc analysis we calculated
logistic regression models with stepwise forward se-
lection to explore possible predictors of maintenance
of treatment and the predictors of relapse. Cut-off for
the inclusion of a variable into the reduced model was
a p-value of ≤0.1. Variables included into the main-
tenance of medication model comprised sex, employ-
ment, stable social environment, somatic comorbidity,
psycho-education, number of manic, depressive and mixed
episodes, overall number of episodes, rapid cycling, CGI-
BP total, manic and depressive, CGI-S psychotic symp-
toms, CGI-T, hospitalization, psychiatric comorbidity,
alcohol consumption, adherence and DAI at baseline,
age, age at first bipolar symptoms, first manic or mixed
episode and first depressive episode. The same variables,
with exception of hospitalization and CGI-T were used in
the relapse model.
To further analyze subgroups of interest, patients were
stratified into treatment cohorts by mood stabilizing ther-
apy at baseline. Less frequent medications were grouped
together by substance class and type of combination to
allow for reasonable statistical analysis (cohort size). Treat-
ment with antidepressants was not included in the cohort
definition but is reported below as concomitant medica-
tion. Cohorts were formed as follows:
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Lithium monotherapy: LM, N = 152
Anticonvulsant monotherapy: AM, N = 216
Olanzapine/lithium combination therapy: OLC, N = 47
Olanzapine/anticonvulsant combination therapy:
OAC, N = 68
Other combinations of mood-stabilizers: OC, N = 48
Other mood stabilizing therapy: OMS, N = 44
At Visit 1 64.91% of all patients received concomitant
psychiatric medication. OC comprises any combination
containing at least one of the following: olanzapine, lith-
ium or anticonvulsant (lamotrigine, valproic acid, carba-
mazepine, oxcarbazepine). OMS patients received other
substances which were given aiming for mood-stabilization
(like risperidone, quetiapine, clozapine, amisulpride).
Results
Patient disposition and early discontinuation
Patients could be included into the study at the investiga-
tor’s discretion. Overall, 761 patients were documented
and evaluated. Of these, 545 (71.6%) patients reached the
endpoint at 18 months. Early discontinuation was reported
in 216 (28.4%) patients. Overall, the most frequent reasons
for discontinuation were lost to follow-up (63 patients,
8.3%) and patient decision (30 patients, 3.9%). For 114
(15.0%) patients no reason for early discontinuation was
specified. For the three largest cohorts AM, OM, and LM
reasons for switching to another mood stabilizing therapy
due to adverse events were reported by investigators for 13
(6.02%) AM patients, 12 (6.45%) OM patients, and 13
(5.26%) LM patients. Lack of efficacy was the reason to dis-
continue treatment for 25 (13.89%) AM, 20 (10.75%) OM,
and 9 (5.92%) LM patients. For 30 (13.89%) AM, 29
(15.59%) OM, and 3 (1.97%) LM patients discontinuations
were reported as subject decision. No switch was reported
for 122 patients (56.48%) in the AM, for 99 patients
(53.23%) in the OM, and 101 (66.45%) in the LM cohort.
The combination therapies are not listed here as switches
may be due to multi-factorial reasons. Additionally, each of
these groups had less than 70 patients, being a minor frac-
tion of the dataset.
Baseline demographics and characteristics
The mean age of patients was 48.0 years. The age ranged
between 18 and 83, with 50% (Q25 - Q75) aged be-
tween 39 and 56 years 434 (57%) patients of all patients
(N = 761) were female. OLC was the only cohort with a
majority of males (86 patients, 61.7%). About one third
of the patients were in employment, most patients lived
in a stable social environment (678 patients; 89.1%).
267 (35.1%) patients reported alcohol consumption, 31
(4.1%) alcohol abuse or addiction, and 20 (2.6%) the
consumption of illicit drugs.A history of diabetes mellitus was found in 34 (4.5%)
patients, lipid metabolism disorder in 56 (7.4%), and car-
diovascular disease in 77 (10.1%) patients. Overall, 220
(28.9%) patients were diagnosed with additional psychi-
atric disorders according to ICD-10 [20]. Of those, the
most frequent diagnostic groups were: disorders of adult
personality and behavior [F60–69]: (65 patients, 8.8%),
neurotic, stress-related and somatoform disorders [F40-
48]: (63 patients, 8.6%), mental and behavioral disorders
due to psychoactive substance use [F10-19]: (42 patients,
5.7%) and schizophrenia, schizotypal and delusional dis-
orders [F20–29]: (33 patients, 4.5%). In the different co-
horts, the rate of concomitant psychiatric disorders
ranged from 51.2% (n = 22) in the OMS cohort to 17.7%
(n = 12) in the OAC cohort. The mean number of bipo-
lar episodes since start of the disorder by cohort ranged
from 8 to 10, except in OC (mean of 111 bipolar epi-
sodes, median 10), which comprised one ultra-rapid cy-
cler who was reported with a number of 2000 episodes
(confirmed by treating psychiatrist). In addition, there
were 76 (10.0%) patients with rapid cycling. The mean
numbers of manic, depressive and mixed episodes in the
overall sample within the last 12 months were 1.1, 1.7
and 0.8, respectively. Thirty six point four percent of the
patients had been hospitalized due to psychiatric disor-
ders during the 12 months prior to the study, with rates
ranging between 45.5% (OMS) and 30.3% (LM). On
average, patients had been treated with mood stabilizers
for 3.9 years (SD 4.5) before entering the study. In the
treatment cohorts, this time span ranged from 2.1 years
(OM) to 7.2 years (OC). One quarter in the LM group
had been on at least one mood stabilizer for more than
10 years (upper quartile 10.1 years). A history of suicide
attempts was reported for 193 (25.4%) patients, with
rates of 37.5% (n = 18) seen in OC and of 17.0% (n = 8)
in OLC. Further details of the baseline characteristics by
treatment cohorts are given in Table 1.
Time on mood stabilizing treatment
After 540 days (18 months, corresponding to Visit 7)
87.7% patients of the overall sample were still on the
same mood-stabilizing medication they received at base-
line (CI 85.1; 90.0). The respective retention rates for the
cohorts were: OM 88.1% (CI 82.1; 92.1), LM 93.6% (CI
88.0; 97.0), AM 83.8% (CI 77.8; 88.3), OLC 87.1% (CI 73.4;
94.0), OAC 86.8% (75.2; 93.1), OC 84.2% (CI 69.7; 92.2),
OMS 85.9% (CI 71.3; 93.4). Concomitant antidepressant
medication was prescribed to 41.65% of all patients at
Visit1 and to 32.77% on Visit 7 (V7). At V1 18.13%
received selective serotonin reuptake inhibitors (SSRIs),
12.48% tricyclic antidepressants (TCAs), and 8.41% sero-
tonin/ noradrenaline reuptake inhibitors (SNRIs).
The median (Q1/Q3) time on mood stabilizing treat-
ment, calculated from baseline, ranged between 484.0
Table 1 Baseline demographics and characteristics
Variable Total sample
N = 761
OM
N = 186
LM
N = 152
AM
N= 216
OLC
N = 47
OAC
N = 68
OMS
N = 44
OC
N = 48
Continuous variables mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD)
Age [years] 48.0 (12.7) 47.8 (13.4) 50.5 (13.5) 46.4 (12.2) 48.9 (11.1) 48.0 (13.0) 44.8 (12.3) 49.7 (9.1)
BMI [kg/m2] 26.9 (4.7) 26.4 (4.2) 26.6 (4.2) 27.4 (5.5) 27.5 (4.1) 26.9 (4.9) 25.8 (3.7) 27.4 (4.9)
Age at first symptoms [years] 31.3 (11.5) 31.5 (11.2) 32.9 (12.7) 30.4 (11.4) 32.4 (10.1) 31.3 (10.5) 28.4 (11.6) 31.5 (11.4)
BP-episodes since start of disease
[mean (SD) median]
15.5 (97.6) 6* 8.3 (16.8) 5 8.6 (9.3) 6 10.2 (11.7) 7 10.4 (10.4) 6 8.2 (7.4) 6 8.9 (6.7) 7.5 111.1 (378.7) 10*
No. of manic episodes within last
12 months
1.1 (1.2) 1.1 (1.0) 0.9 (1.2) 0.9 (1.1) 1.0 (1.2) 1.2 (1.1) 1.7 (1.5) 1.5 (1.6)
No. of depressive episodes within last
12 months
1.7 (1.3) 1.7 (1.3) 1.5 (1.3) 1.7 (1.3) 1.6 (1.4) 1.6 (1.4) 1.9 (1.3) 2.4 (1.6)
No. of mixed episodes within last
12 months
0.8 (1.3) 0.7 (1.2) 0.5 (0.9) 0.7 (1.2) 0.8 (1.4) 0.8 (1.1) 1.1 (1.6) 1.7 (2.0)
Time on mood stabilizing therapy [years] 3.9 (4.5) 2.1 (1.4) 6.7 (6.1) 2.9 (2.4) 6.1 (6.3) 2.7 (1.8) 2.5 (2.9) 7.2 (7.8)
Binary variables n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Sex, male 327 (43.0) 86 (46.2) 73 (48.0) 75 (34.7) 29 (61.7) 31 (45.6) 16 (36.4) 17 (35.4)
Paid employment 264 (34.7) 61 (33.2) 49 (32.9) 84 (39.6) 18 (38.3) 24 (36.9) 14 (32.6) 14 (29.2)
Stable social environment 678 (89.1) 165 (89.7) 141 (94.0) 193 (91.0) 45 (95.7) 55 (84.6) 39 (90.7) 40 (83.3)
Rapid cycling 76 (10.0) 15 (8.9) 17 (11.7) 20 (9.5) 0 (0.0) 6 (9.8) 4 (9.3) 14 (33.3)
Hospitalized due to psychiatric disease
(last 12 months)
277 (36.4) 71 (38.2) 46 (30.3) 75 (34.7) 20 (42.6) 25 (36.8) 20 (45.5) 20 (41.7)
Further psychiatric diseases 220 (28.9) 55 (30.4) 37 (26.2) 66 (31.1) 10 (21.7) 12 (17.7) 22 (51.2) 18 (39.1)
Alcohol consumption 267 (35.1) 53 (28.5) 67 (44.1) 71 (32.9) 18 (38.3) 20 (29.4) 18 (40.9) 20 (41.7)
Alcohol abuse or addiction 31 (4.07) 8 (1.05) 6 (0.79) 6 (0.79) 3 (0.39) 2 (0.26) 1 (0.13) 5 (0.66)
Illicit drug use 20 (2.6) 2 (1.1) 6 (3.9) 8 (3.7) 2 (4.3) 0 (0) 2 (4.5) 0 (0)
History of suicide attempts 193 (25.4) 40 (21.5) 46 (30.3) 46 (21.3) 8 (17.0) 22 (32.4) 13 (29.5) 18 (37.5)
Abbreviations: BMI body mass index, BP bipolar, SD standard deviation, OM olanzapine monotherapy, LM llithium monotherapy, AM anticonvulsant monotherapy,
OLC olanzapine-lithium combination therapy, OAC olanzapine-anticonvulsant combination therapy, OMS other mood stabilizing therapy, OC other combinations,
N number of patients.
*High mean and SD due to ultra rapid-cycling patient with 2000 episodes confirmed by investigator.
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dian time to a change of treatment was 525.0 days
(374.0/554.0). Patients on lithium (534.0 days, 485.5/553.5)
stayed on their medication longer than those from the co-
horts OM (519.5 days, 335.0/548.0) and OMS (484.0 days,
230.0/531.0).
After 540 days (18 months), 87.7% of patients of the
overall sample were still on the same mood stabilizing
medication they had been taking at baseline (95% CI
85.1; 90.0).
Primary analysis
Figure 1 shows the Kaplan-Maier curves for time to re-
lapse for the cohorts. A CGI-BP worsening of a mini-
mum of 2 points, a CGI-BP increase to >3 after baseline,
hospitalization due to psychiatric disorders, and death
related to bipolar disorder were regarded as an event
(i.e. relapse). Patients who dropped out or died from othercauses were considered censored. Furthermore, pa-
tients were considered censored if they changed their
mood stabilizing therapy. At Visit 7 (18 months), 74.0% of
the patients in the overall sample were without relapse.
The percentages for the cohorts were: OM 78.5% (95% CI
71.5; 84.0), LM 80.2% (95% CI 72.7; 85.8), AM 68.9% (95%
CI 62.0; 74.9), OLC 64.2% (95% CI 49.3; 75.8), OAC 74.4%
(95% CI 61.0; 83.8), OC 58.4% (95% CI 43.1; 71.0), OMS
78.7% (95% CI 62.8; 88.4).
The proportion of patients without hospitalization due
to psychiatric disorders while in the study ranged from
69.5% (OC) to 90.7% (OM) with 95% CI for the observed
differences ranging between 53.8 - 80.8 and 85.0 - 94.3,
respectively.
Duration on mood stabilizing treatment
The Cox- proportional hazard regression (Figure 2, with
OM as reference) shows that patients treated with OMS
Table 2 Time on mood stabilizing treatment since baseline and retention rates during the study
Cohort N Mean
[days]
95% CI
[days]
SD
[days]
1st Quartile
[days]
Median
[days]
3rd Quartile
[days]
Retention-Rate
(%)
95% CI
(%)
OM 186 433.5 408.4 - 458.5 173.0 335 520 548 88.1 82.1 - 92.1
LM 152 481.3 458.7 - 504.0 141.2 486 534 554 93.6 88.0 - 96.6
AM 216 440.4 416.8 - 464.0 175.8 363 527 558 83.8 77.8 - 88.3
OLC 47 475.1 428.4 - 521.8 159.1 454 538 570 87.1 73.4 - 94.0
OAC 68 417.5 371.1 - 463.9 191.8 262 514 552 86.8 75.2 - 93.2
OC 48 462.2 413.9 - 510.5 166.3 403 529 568 84.2 69.7; 92.2
OMS 44 377.5 318.8 - 436.2 193.1 230 484 531 85.9 71.3; 93.4
Total sample 761 444.7 432.5 - 456.9 171.2 374 525 554 87.7 85.1 - 90.0
Abbreviations: OMOlanzapine monotherapy, LM Lithium monotherapy, AMAnticonvulsive monotherapy, OLCOlanzapine/lithium combination therapy, OACOlanzapine/
anticonvulsive combination therapy, OCOther combinations of mood-stabilizers, OMSOther mood stabilizing therapy, SD standard deviation, CI confidence interval.
Start date was start of documentation. The end date was date of either the first discontinuation or switch of mood stabilizing medication, death, or the last
documented visit.
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tion than in OM. Patients treated with LM had about a
2-fold chance to continue their treatment compared
to patients treated with OM. Factors associated with a
greater risk of discontinuing the primary mood stabilizing
therapy were living in a non-stable social environment, last
bipolar episode more severe, comorbid psychiatric diseases,
and rapid cycling (Figure 3).
At baseline, the mean DAI score was 5.8 (95% CI 5.5
to 6.1) for the overall sample. The score increased to 6.8Figure 1 Kaplan-Meier plot for total relapse-free-time by treatment c
(N = 761). Definition of relapse: CGI-BP worsening of a minimum of 2 point
bipolar disease were counted as an event (i.e. relapse). Patients who dropp
mood stabilizing therapy were considered censored. Abbreviations: OM=Olan
monotherapy, OLC =Olanzapine/lithium combination therapy, OAC =Olanzap
mood-stabilizers, OMS =Other mood stabilizing therapy.(95% CI 6.5 to 7.1) after 18 months of observation. By
cohorts the mean DAI score ranged between 5.1 (OMS)
and 6.9 (OAC) at baseline and between 6.2 (OMS) and
8.2 (OAC) at 18 months. At baseline the DAI (95% CI)
was lower for OM (5.65; 5.07, 6.22) compared to OLC
(6.87, 5.94, 7.80) and OAC (6.89; 6.02, 7.75). The mean
DAI score improved for all cohorts during the course of
the study. At 18 months the DAI was higher for OAC
(8.20; 7.52, 8.87) compared to OM (6.72; 6.09, 7.34), LM
(6.41; 5.65, 7.17) and AM (6.60; 6.09, 7.11).ohort with change of treatment considered censored. All patients
s, hospitalization due to psychiatric disease, and death related to
ed out or died from other causes and patients who changed their
zapine monotherapy, LM= Lithium monotherapy, AM=Anticonvulsive
ine/anticonvulsive combination therapy, OC =Other combinations of
Figure 2 Cox regression: Hazard ratios of treatment cohorts for the discontinuation of primary mood stabilizing therapy with
olanzapine monotherapy (OM) as reference. Abbreviations: OM = Olanzapine monotherapy, LM = Lithium monotherapy, AM = Anticonvulsive
monotherapy, OLC = Olanzapine/lithium combination therapy, OAC = Olanzapine/anticonvulsive combination therapy, OC = Other combinations
of mood-stabilizers, OMS = Other mood stabilizing therapy.
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ance were alcohol consumption (advantage for consump-
tion), baseline adherence (advantage for good baseline
adherence), number of manic episodes (advantage for less
episodes) and baseline CGI-BP (advantage low CGI ≤3).
(Details of the model are given in Table 3).
Remission, stability and relapses
The CGI-BP score was dichotomized into patients with a
CGI-BP-total of ≤3 (criterion of remission) and patients
with a CGI-BP >3 (criterion of relapse after baseline). At
baseline, 642 (84.5%) patients fulfilled the criterion of
remission, which implies that 118 (15.5%) patients actu-
ally had not met one of the inclusion criteria. However, aFigure 3 Risk for discontinuation of primary mood stabilizing therapy. A
monotherapy, LM= Lithium monotherapy, AM= Anticonvulsive monotherapy,
anticonvulsive combination therapy, OC =Other combinations of mood-stabilisensitivity check, excluding these patients, revealed that
this hardly affected the overall results.
At Visit 7, 459 (85.0%) patients had a CGI-BP total of ≤3.
The respective rates in the cohorts were similar at both
visits. The logistic regression model yielded a higher num-
ber of depressive episodes, higher baseline CGI-BP total
score and higher CGI-BP depressive scores at baseline (see
Table 4) as predictors for relapse.
Safety and tolerability
CGI-tolerability
Poor tolerability (CGI-tolerability score ≥3) was reported
by 55 (7.6%) patients at baseline and by 28 (5.3%) at
Visit 7. In the cohorts the rates ranged between 6.2%ssociation with solicited factors (Cox). Abbreviations: OM=Olanzapine
OLC =Olanzapine/lithium combination therapy, OAC =Olanzapine/
zers, OMS =Other mood stabilizing therapy.
Table 3 Factors significantly associated with maintenance
of treatment
Factor Odds ratio 95% CI p-value
Baseline adherence (no vs. yes) 0.013 0.001 – 0.146 0.0004
Manic episodes (no vs. >1) 12.953 2.773 – 60.504 0.0011
Manic episodes (1 vs. >1) 8.209 2.131 – 31.620 0.0022
CGI BP total (≤3 vs. >3) 10.971 2.018 – 59.651 0.0056
Alcohol consumption (any vs. no) 4.563 1.287 – 16.181 0.0188
Abbreviations: CGI BP Clinical Global Impression Score Bipolar,
CI confidence interval.
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3.1% (OC) and 8.3% (OMS) at Visit 7.Treatment-emergent adverse events
Overall, TEAEs were reported by 113 (14.9%) patients,
78 of these (10.3%) had AEs classified as related to medi-
cation. Eight patients were reported with SAEs: one
patient from the LM cohort experienced a lithium over-
dose which was the only SAE considered to be related to
the mood stabilizing therapy. The same patient was also
reported with syncope. Other SAEs were: 1 appendec-
tomy, 1 breast cancer, 1 retinal detachment and 4 deaths.
2 women from the OC cohort, 47 and 64 years old, died
during the observational period. No further information
could be obtained for the circumstances of death in
these patients. One 67-year old man from the AM co-
hort died of myocardial infarction, and one 54 year old
woman from the OLC cohort committed suicide. This
latter patient was in acute mania and was reported as
having insufficient adherence. None of these cases was
considered related to the mood stabilizing therapy by
the treating study physician, though, due to lack of infor-
mation, this cannot be ruled out completely for the two
fatalities in the OC cohort. An overview on TEAEs in
the cohorts is given in Table 5.
Weight gain as TEAE was reported in 42 (5.5%) pa-
tients (OM 12; 6.5%, LM 7; 4.6%, AM 9; 4.2%, OLC 3;
6.4%, OAC 3; 4.4%, OC 2; 4.2%, OMS 6; 13.6%), tremor
in 13 (1.7%) patients (LM 5; 3.3%, AM 3; 1.4%, OLC 3;
6.4%, OC 1; 2.1%, OMS 1; 2.3%). Vomiting occurred in 3Table 4 Factors significantly associated with relapse
Factor Odds ratio 95% CI p-value
CGI BP total (≤3 vs. >3) 0.118 0.046 – 0.302 <0.0001
CGI BP last depressive episode
(≤3 vs. >3)
3.642 1.506 – 8.804 0.0041
No. of depressive episodes (1 vs. >1) 3.401 1.407– 8.220 0.0066
Duration of depressive episodes
(per year)
0.967 0.935 – 1.000 0.0473
Abbreviations: CGI BP Clinical Global Impression Score Bipolar, CI confidence interval.(1.4%) patients of the AM cohort. All other types of
TEAEs were reported with rates <1% of the overall sam-
ple, and occurring in <3 patients per cohort.
Solicited adverse reactions
Six hundred and sixty-two (87.0%) patients reported at
least one adverse event from the solicited list at least
once in the course of the study. The proportion of pa-
tients reporting solicited adverse reaction in the cohorts
ranged from 95.7 (OLC) to 79.6 (OMS). The adverse re-
action reported most frequently throughout all cohorts
was weight increase, with rates ranging from 89.4%
(OLC) to 59.1% (OMS). Details are given in Table 6.
Weight gain and sedation were more prevalent in cohorts
with olanzapine mono- or combination therapy, while
cohorts receiving lithium mono- or combination therapy
had higher rates of tremor, thirst, and gastrointestinal
complaints.
Discussion
Though the majority of the patients were of the same
age group (i.e. middle-aged), considerable diversity in
the characteristics of their disease was observed (i.e.,
duration, severity, number, type of episodes). In contrast
to randomized trials, the composition of the therapy co-
horts in this study is diverse: the baseline data suggest
that the regimens chosen are the result of differential
considerations of the treating psychiatrists according to
their patients’ history and needs [22].
The observed discontinuation rate of 28.4% in our
study was low compared to rates observed in controlled
clinical trials [13,17]. Furthermore, we found comparably
high retention rates in all treatment cohorts, even though
the patients in these cohorts differed perceptibly in clinical
preconditions. In general, patients on lithium tended to re-
tain their medication longer, and discontinued less often
than patients in any of the other cohorts. As lithium is one
of the oldest and most established medications for the
treatment of bipolar disease, a high percentage of patients
in this group has been taking this medication for a long
period of time (some >10 years). As patients would hardly
retain a medication this long if they were not comfortable
with it, the implication is that in the lithium group we ob-
serve a pre-selection of rather satisfied and therefore com-
pliant patients. Kessing et al [23] in 2007 published data
from a Danish medical register study with the finding
for lithium that the mean time to discontinuation was
181 days. The discrepancy in time on medication to our
observation might again be due to the patient population
on a long standing lithium medication, who had passed the
time point of early discontinuation found in the same pub-
lication to be at 45.2 days for 25% of patients.
In contrast, the OC and OMS cohorts comprised more
difficult-to-treat patients: patients with mixed episodes,
Table 5 Treatment-emergent adverse events (TEAEs), overview of all patients (N = 761)
Patients with: Total sample
N = 761
OM
N = 186
LM
N = 152
AM
N = 216
OLC
N = 47
OAC
N = 68
OC
N = 48
OMS
N = 44
N % N % N % N % N % N % N % N %
Any TEAE 113 14.9 21 11.3 27 17.8 31 14.4 9 19.2 8 11.8 7 14.6 10 22.7
Related TEAE 78 10.3 14 7.5 19 12.5 23 10.7 6 12.8 6 8.8 3 6.3 7 15.9
Any SAE 8 1.1 0 0.0 3 2.0 1 0.5 1 2.1 0 0.0 2 4.2 1 2.3
Related SAE 1 0.1 0 0.0 1 0.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
TEAE leading to discontinuation 7 0.9 0 0.0 2 1.3 1 0.5 1 2.1 0 0.0 2 4.2 1 2.3
Lethal outcome 4 0.5 0 0.0 0 0.0 1 0.5 1 2.1 0 0.0 2 4.2 0 0.0
Abbreviations: N number of patients, OMOlanzapine monotherapy, LM Lithium monotherapy, AM Anticonvulsive monotherapy, OLC Olanzapine/lithium
combination therapy, OACOlanzapine/anticonvulsive combination therapy, OC Other combinations of mood-stabilizers, OMSOther mood stabilizing therapy,
TEAE treatment emergent adverse events, SAE serious adverse events.
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tended to suffer more often from additional psychiatric ill-
nesses, experience more hospitalizations, less clinical im-
provement, reach remission status less frequently, switch
to new medications earlier, and have a less positive attitude
towards their medication.
The various treatment cohorts were largely compar-
able with regard to time on mood stabilizing medication.
Though the longest time on mood stabilizing therapyTable 6 Descriptive analysis of patients with solicited adverse
All Patients
N = 761
OM
N = 186
LM
N = 152
Solicited side effects n % n % n %
Any 662 87.0 157 84.4 135 88.8
Weight increase 530 69.7 144 77.4 99 65.1
Sedation 369 48.5 100 53.8 56 36.8
Cognitive dysfunctions 321 42.2 74 39.8 68 44.7
Sexual dysfunctions 294 38.6 78 41.9 48 31.6
Gastroint. disorders 221 29.0 40 21.5 58 38.2
Dizziness 215 28.3 46 24.7 44 29.0
Tremor 195 25.6 25 13.4 62 40.8
Thirst 169 22.2 30 16.1 58 38.2
Insomnia 165 21.7 41 22.0 33 21.7
Polyuria/nycturia 109 14.3 21 11.3 49 32.2
Menstrual disorders 65 8.5 16 8.6 11 7.2
Thyroid disorders 58 7.6 5 2.7 31 20.4
Akathisia 54 7.1 12 6.5 7 4.6
Parkinson syndrome 21 2.8 3 1.6 5 3.3
Hyperprolactinaemia 18 2.4 3 1.6 5 3.3
Tardive dyskinesia 16 2.1 1 0.5 4 2.6
Dystonia 16 2.1 2 1.1 2 1.3
QTc-Prolongation 8 1.1 0 0.0 3 2.0
Abbreviations: N number of patients, OMOlanzapine monotherapy, LM Lithium mon
therapy, OACOlanzapine/anticonvulsive combination therapy, OCOther combinationwas seen in LM, the difference was only notably large
compared to OM and OMS. No further notable differ-
ences were observed between the cohorts. In addition,
there was no relevant difference at all in the retention
rates. The hazard for discontinuation was also compar-
able in most cohorts. Only in LM the risk was lower than
in OM. In AM and OMS it was higher than in OM. This
observation, as well as other factors found associated
with increased risk of discontinuation (non-stable socialevents, all patients (N = 761)
AM
N = 216
OLC
N = 47
OAC
N = 68
OC
N =48
OMS
N = 44
n % n % n % n % n %
185 85.7 45 95.7 61 89.7 44 91.7 35 79.6
140 64.8 42 89.4 49 72.1 30 62.5 26 59.1
101 46.8 27 57.5 37 54.4 23 47.9 25 56.8
78 36.1 25 53.2 36 52.9 26 54.2 14 31.8
79 36.6 30 63.8 33 48.5 15 31.3 11 25.0
59 27.3 16 34.0 15 22.1 19 39.6 14 31.8
64 29.6 13 27.7 19 27.9 15 31.3 14 31.8
35 16.2 22 46.8 23 33.8 22 45.8 6 13.6
36 16.7 18 38.3 12 17.7 10 20.8 5 11.4
46 21.3 12 25.5 12 17.7 14 29.2 7 15.9
16 7.4 12 25.5 5 7.4 4 8.3 2 4.6
23 10.7 2 4.3 6 8.8 4 8.3 3 6.8
7 3.2 7 14.9 2 2.9 6 12.5 0 0.0
18 8.3 1 2.1 9 13.2 3 6.3 4 9.1
6 2.8 1 2.1 3 4.4 2 4.2 1 2.3
3 1.4 3 6.4 3 4.4 0 0.0 1 2.3
7 3.2 1 2.1 1 1.5 2 4.2 0 0.0
5 2.3 1 2.1 0 0.0 3 6.3 3 6.8
3 1.4 0 0.0 1 1.5 1 2.1 0 0.0
otherapy, AM Anticonvulsive monotherapy, OLCOlanzapine/lithium combination
s of mood-stabilizers, OMSOther mood stabilizing therapy.
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cycling) matches well with the notion that OMS com-
prised patients who were rather difficult to treat. A simi-
lar but less pronounced tendency could be observed for
the OC cohort. It should be noted that in this cohort
with combinations of less frequently used mood stabiliz-
ing agents, the highest proportion of patients with rapid
cycling was found.
The drug attitude measured as DAI was positive and
high from the start in all cohorts, indicating that the ma-
jority of these outpatients had a positive attitude re-
garding their medication at the start of the study. It
improved only slightly over the course of the study. This
might result from several factors: 1) the selection criteria
of stabilization, 2) the natural treatment setting where
physicians are familiar with their patients through a long-
lasting therapeutic relationship, and 3) increased adher-
ence through the patients’ awareness of taking part in a
study. Quite in line with this, good baseline adherence
was found to be one predictor of adherence throughout
the study, while a higher number of manic episodes and
a high baseline CGI were predictors of non-adherence:
OMS had the highest number of manic episodes, the
highest percentage of patients with a baseline CGI-BP >3,
and the lowest DAI.
Interestingly, alcohol consumption was positively asso-
ciated with adherence. The variable in the model was
“any consumption”, and 35.1% of the patients reported
consumption, whereas only 4.1% stated alcohol abuse or
addiction. One could speculate, that this observation
possibly could reflect the occasional social drink, which
might be an indicator of social integration presumably
associated with general well-being and stability.
The majority of patients were without relapse at Visit
7 (day 540), rates between the cohorts were largely similar.
The only notable difference was seen in OC compared to
OM and LM which corresponds with the predictors found
in the logistic regression model. OC had indeed the highest
number of depressive episodes and also the highest num-
ber of patients with a CGI-BP >3.
As a CGI-BP of ≤3 was an inclusion criterion, there
was little room for improvement, and thus the CGI-BP
scores decreased only slightly over time in all cohorts.
Correspondingly, the rates of patients with a CGI-BP ≤3
were around 80% to 90% in all cohorts at both visits,
with only minor variations in both directions. The aim
of the maintenance treatment, i.e. stabilization, could
thus be regarded as achieved.
Due to the observational design of the study and the
determination of the mood stabilizing medication that
was chosen for the individual patient according to clin-
ical reasoning, a comparison between the different co-
horts of medications and combinations is not intended
and not possible. We should stress the point that patientenrollment to the study was at the discretion of the
treating physician. Therefore, results have to be interpreted
in the context that medication and patients were selected
on the basis of their individual preferences and history. In
summary, the different treatments we observed achieved
similar effects regarding maintenance treatment of bipolar
disease. This is surprising regarding the diversity of the
patients’ disease and social characteristics at the start of
documentation, hinting again at the capability of physi-
cians and their patients to optimize individual treatment
using the spectrum of medications available. Thus, this
trial design mimics clinical treatment reality better than a
randomized study taking into account physicians’ skills
and patient diversity. Besides the classic treatments with
lithium and anticonvulsants, olanzapine was found to be
a relevant mood stabilizing treatment option for a consid-
erable number of patients in this German study sample.
Other atypical antipsychotics were also used in clinical
practice, but as these had not yet been approved for the
treatment of bipolar disease at the start of the study, they
were applied in few patients only (OMS-cohort).
Only small numbers of patients were reported with
TEAEs or adverse events as assessed by the CGI-
tolerability.
On the other hand, 87.0% of the overall sample
reported at least one adverse event at least once over
the course of the study on the predefined solicited check-
list of side effects specific for the various mood stabilizing
medications. Obviously, these effects were observed, but
not judged by the patients to be relevant enough to be
reported spontaneously as AEs. Solicited adverse events
also were no reason for physicians or patients to stop or
switch medication.
Within the cohorts, OLC patients reported the highest
overall number and variety of solicited adverse events,
closely followed by the OC groups (which also included
patients receiving lithium plus one or several other sub-
stances for mood stabilization). Compared to LM it ap-
pears that these patients experienced adverse events of
lithium as well as typical ones for the other mood stabi-
lizers. In all cohorts, the most common AE was weight
gain. This underlines the potential risk of weight gain in
the maintenance therapy of bipolar disorder, the need to
monitor and if necessary to treat bipolar patients for
metabolic-related adverse events.
Conclusion
The data from this observational study in Germany
show that a wide range of medication is used to provide
individual mood stabilizing therapies to single patients.
The finding that physicians and their patients achieved
comparably satisfactory results, despite diversity in
disease and individual patients shows that medications
are used by physicians with great knowledge and with
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ical practice.
Beside the classical mood stabilizers like lithium or anti-
convulsants there is an increasing use of atypical anti-
psychotic medications like olanzapine in the maintenance
therapy of bipolar disorders. Combination seems to be
chosen mainly for difficult to treat patients with a high bur-
den of disease.
Limitations
Several limitations should be considered in this study
performed by Lilly Germany: The treatment regimens
were not randomized, but chosen by the treating psychi-
atrists according to the patient’s individual need, which
created selection bias in the way that we see patients
with more severe symptoms accumulate in some groups
while other cohorts comprise predominately the more
stable ones. In addition, the protocol did not advise the
physicians to enroll patients consecutively, which could
possibly have led to some additional selection bias.
Patients were stratified into treatment cohorts post
hoc. Considering that there had been no restriction re-
garding the medication applied for mood stabilization, a
large variety of substances was employed, but only few
in a frequency which allowed the formation of mono-
therapy cohorts with patient numbers large enough for
reasonable evaluation. The remainder therefore had to
be grouped by substance type and type of combination.
Even then there remained considerable differences in
sample sizes per treatment cohort; hence these differ-
ences should be considered with caution.
At the time when this study was started, olanzapine
was the only antipsychotic approved for maintenance
treatment of bipolar disease in Germany. It was there-
fore the only substance of this class which was used fre-
quently enough to form a substantial cohort. However
we saw other antipsychotics applied as mood stabilizers
in clinical practice, which were not yet approved in
Germany for this indication, but for which some evidence
had been generated at the time that they might be effect-
ive. As a consequence, these were employed infrequently,
seemingly as a last resort, in cases especially difficult to
treat (e.g. rapid cyclers, patients with mixed episodes).
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